慢性髓性白血病患者TKI停药无治疗缓解研究进展

Study progress of TKI discontinuation with treatment-free remission in patients with chronic myeloid leukemia

酪氨酸激酶抑制剂(TKI)的使用显著改变了慢性髓性白血病(CML)患者的生存及预后,但长期用药带来的经济负担和药物不良反应使得无治疗缓解(TFR)成为CML治疗研究的新目标。逐年增加的TKI停药临床试验显示,50%左右CML患者可获得TFR,具有一定的安全性和有效性,且严格把控TFR预测因子将有助于CML患者成功实现无治疗缓解。该文旨在对TKI停药的TFR的临床研究进展进行综述。

The use of tyrosine kinase inhibitors(TKIs)has dramatically improved the survival and prognosis of the patients with chronic myeloid leukemia(CML).But the economic burden and drug adverse reactions led by long medication make the treatment-free remission(TFR)to become a new goal of CML treatment study.The annual increase in TKI withdrawal clinical trials showed that 50%of CML patients can obtain TFR,which has a certain safety and effectiveness,moreover strictly controlling the TFR predictive factor will contribute to successfully realize TFR in the patients with CML.This article goal aims to review the study progress on TFR of TKI withdrawal.